2023 PM Society Awards – Winners Announced
21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board
24th March 2023
21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board
24th March 2023
Study shows significant reduction of nasal S. aureus in cardiac surgery patients before surgery
24th March 2023
The multi-centre international clinical trial will evaluate company’s Debio 0328 candidate
24th March 2023
The partnership will involve progressing macrophage-targeting antibody treatment for cancer
23rd March 2023
Eladocagene exuparvovec is for children with ultra-rare genetic disorder in final draft guidance
23rd March 2023
Study involves SFX-01 candidate and emerging preliminary pharmacokinetic data from study
22nd March 2023
Measures include a requirement to publicly register studies and share results among research participants
22nd March 2023
Company raises €12m in financing with a view to entering to the European market
21st March 2023
Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer
21st March 2023
Combination therapy treat patients with metastatic castration-resistant prostate cancer
20th March 2023
Company will also operate work on particular initiatives across an additional five neonatal sites
20th March 2023
GOSH will collaborate with Leucid at the Zayed Centre for Research into Rare Disease in Children
17th March 2023
Therapy prevents tumour proliferation while breaking immune tolerance among cancer patients
17th March 2023
Funding is for onasemnogene abeparvovec and concerns babies with spinal muscular atrophy
16th March 2023
Aim for participants will be to quickly new antimicrobial therapies to treat chronic respiratory infections
16th March 2023